First Bank & Trust Buys 29,342 Shares of Pfizer Inc. (NYSE:PFE)

First Bank & Trust grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 69.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 71,785 shares of the biopharmaceutical company’s stock after buying an additional 29,342 shares during the quarter. First Bank & Trust’s holdings in Pfizer were worth $1,992,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Teza Capital Management LLC purchased a new stake in Pfizer during the third quarter valued at about $347,000. Caxton Associates LP increased its stake in Pfizer by 7.2% in the 3rd quarter. Caxton Associates LP now owns 45,018 shares of the biopharmaceutical company’s stock worth $1,493,000 after purchasing an additional 3,043 shares during the period. United Services Automobile Association boosted its stake in shares of Pfizer by 1.5% during the third quarter. United Services Automobile Association now owns 1,510,368 shares of the biopharmaceutical company’s stock valued at $50,099,000 after purchasing an additional 22,731 shares during the period. Bluefin Capital Management LLC bought a new stake in Pfizer during the 3rd quarter valued at $358,000. Finally, White Knight Strategic Wealth Advisors LLC grew its holdings in Pfizer by 3.0% in the 3rd quarter. White Knight Strategic Wealth Advisors LLC now owns 20,528 shares of the biopharmaceutical company’s stock worth $681,000 after acquiring an additional 604 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.6 %

NYSE:PFE opened at $27.98 on Friday. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80. The company’s 50-day simple moving average is $27.90 and its 200 day simple moving average is $27.68. The firm has a market capitalization of $158.55 billion, a P/E ratio of -466.26, a PEG ratio of 1.10 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period in the previous year, the firm earned $1.23 EPS. The business’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PFE shares. Morgan Stanley raised their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $35.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.